Exelixis Inc. Common Stock vs Westinghouse Air Brake Technologies Corporation Common Stock — how do they compare? Exelixis Inc. Common Stock trades at $60.95 (market cap $14.75B), while Westinghouse Air Brake Technologies Corporation Common Stock trades at $285.55 (market cap $48.39B). The key difference: Westinghouse Air Brake Technologies Corporation Common Stock is far larger — about 3.3× Exelixis Inc. Common Stock's market cap, and Westinghouse Air Brake Technologies Corporation Common Stock pays a 0.43% dividend while Exelixis Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 3 Days and Westinghouse Air Brake Technologies Corporation Common Stock for 0 Days on average.
| EXEL | WAB | |
|---|---|---|
Market Cap | $14.75B | $48.39B |
Volume | 2,624,658 | 960,464 |
Sector | Health | Industrials |
52-Week High | $60.99 | $305.79 |
52-Week Low | $34.54 | $193.43 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $14.07B | $54.30B |
Dividend Yield | — | 0.43% |
Signals from Pluang's Aura AI — not financial advice
EXEL trades at $59.51, down 0.52% on the day but near its 52-week high of $61.66 reached on October 12, 2026. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Recent news highlights include a three-month FDA review delay for zanzalintinib but continued growth in CABOMETYX revenue, which surpassed $3 billion annually.
The outlook remains positive with strong profitability metrics (35.33% net margin, 44.39% ROE) and projected revenue growth to $2.4 billion in 2026. Key risks include regulatory delays for new drug approvals and competitive pressures in oncology. Analyst consensus is mixed with 48% buy ratings but a price target of $52.33 suggesting potential downside from current levels.
Wabtec (WAB) trades at $286.51, up 0.26% today, with a neutral technical signal. The company shows strong fundamentals, with Q2 2026 EPS of $2.76 beating estimates and revenue growth to $12.0B projected for 2026. A $700M+ African rail services deal and raised full-year guidance highlight positive business momentum. Key support rests at $284, with resistance at $288.
The outlook is positive, driven by earnings beats, margin expansion, and a robust backlog. Risks include premium valuation (P/E 38.56) and investing cash outflows. Analyst consensus is bullish with a $326.50 price target, suggesting ~14% upside from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →Westinghouse Air Brake Technologies Corporation, known as Wabtec, provides equipment, systems, and services for the freight rail and passenger transit industries. Its Freight segment supplies locomotives, braking systems, and signaling technology, while its Transit segment supports passenger rail systems worldwide.
Read more on WAB →